Biomarkers · Inflammation
Soluble CD14 (sCD14)
Lower values go with lower risk of death. No risk curve catalogued yet.
Published risk of death2.52×high vs low serum sCD14, 10-year all-cause death, fully adjusted (category cut-off not… (95% CI 1.23–5.16) · Australian community-based cohort of 981 individuals without history of CVD, followed 5, 10 and 20 years
What studies found when this marker was changed
They describe what happened in those study groups, not a recommendation. See all catalogued interventions.
Measured changes in sCD14, study by study
3 effects with a numeric size, each from one study arm: the dot is the reported change, the line its 95% interval where one was given. Green points move the marker the way lower risk of death lies; amber the other way. Study results in the groups studied, not predictions for a person.
| Type | Intervention | Reported effect | Evidence | Source |
|---|---|---|---|---|
| pharmacologic | Ruxolitinib (JAK1/2 inhibitor) 10 mg twice daily for 5 weeks added to stable ART in virologically suppressed adults with HIV (ACTG A5336) | Soluble CD14 mean fold change 0.96 vs 1.08 with ART alone by week 5 (relative fold change 0.96, 90% CI .90-1.02); not significant | RCT | Marconi VC, et al. Clinical infectious diseases : an official publication of… |
| pharmacologic | Immediate vs delayed albendazole 400 mg daily in helminth-infected Ugandan adults living with HIV on ART | Serum sCD14 was 1.40 µg/mL (1400 ng/mL; 95% CI -170 to 2980) higher with immediate vs delayed albendazole at 1-month follow-up, not significant (P = 0.06); 24 participants (12 per arm) | RCT | Morawski BM, et al. Am J Trop Med Hyg. 2025;113(6):1300-1310. |
| pharmacologic | Visbiome Extra Strength vs placebo for visbiome extra strength for 25 weeks: Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers | Change in sCD14 From Baseline to Week 25/26: -51.3 ng/mL (95% CI -246 to 143.9) vs placebo for visbiome extra strength at 25 weeks (posted between-group difference, n=93) | RCT | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections… |
| supplement | Oral zinc gluconate 15 mg (men) or 12 mg (women) daily for 18 months vs placebo in ART-naive adults with HIV and heavy alcohol use | Soluble CD14 adjusted mean difference -38.01 ng/mL (95% CI -166.90 to 90.88) vs placebo at 18 months; n=254 | RCT | Freiberg MS, et al. JAMA Netw Open. 2020;3(5):e204330. |